Eqitx appoints chief executive officer
Wednesday, 01 September, 2004
Melbourne-based Equitx (ASX:EQX) has appointed former Agenix vice president Sue Parry-Jones as chief executive officer.
“Sue’s experience in new product development and commercialisation at a number of large pharmaceutical companies including Schering-Plough and Bristol-Myers Squibb, together with her biotechnology industry experience at Agenix and Amgen, have given her an ideal mix of skills to progress the development of our VacTX novel vaccine and ZingoTX Gingerol projects,” said Eqitx Chairman Mr Sol Majteles in a statement. Parry-Jones was most recently vice president of Molecular Diagnostic Imaging at Agenix.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
